Pharmaceutical Biotechnology
DOI: 10.1007/0-306-47384-4_3
|View full text |Cite
|
Sign up to set email alerts
|

The Discovery and Development of Angiotensin II Antagonists

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
30
0

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 26 publications
(30 citation statements)
references
References 49 publications
0
30
0
Order By: Relevance
“…In 1982, Furukawa and coworkers discovered some benzylsubstituted imidazoles that were specific Ang-II antagonists [129]. These compounds served as leads to develop losartan [130], the first commercially available AT 1 antagonist, and valsartan [131] (structures 6 and 7) (Fig. 2).…”
Section: Ace Inhibitorsmentioning
confidence: 97%
“…In 1982, Furukawa and coworkers discovered some benzylsubstituted imidazoles that were specific Ang-II antagonists [129]. These compounds served as leads to develop losartan [130], the first commercially available AT 1 antagonist, and valsartan [131] (structures 6 and 7) (Fig. 2).…”
Section: Ace Inhibitorsmentioning
confidence: 97%
“…LSR, the potassium salt of 2-n-butyl-4-chloro-5-hydroxymeth-yl-1-[(2%-(1H-tetra-zol-5-yl)biphenyl-4-yl)methyl]imidazole is a competitive nonpeptide angiotensin II antagonist, first marketed in 1995. It is recommended for treating hypertension [12] and hypertensive patients with diabetic nephropathy. It is available alone or in combination with other low dose thiazide diuretic to achieve an additive antihypertensive effect.…”
Section: Introductionmentioning
confidence: 99%
“…Losartan potassium is a highly specific, nonpeptide angiotensin II antagonist indicated for the treatment of hypertension [5]. It blocks the renin-angiotensin system by suppressing the effects of angiotensin II at its receptors [6], It is a weakly acidic yellowish white crystalline powder with a pK a of 4.9.…”
Section: Introductionmentioning
confidence: 99%